内容紹介
Summary
A 70-year-old woman was diagnosed with cT2N2M0 left triple negative breast cancer. She received neoadjuvant chemotherapy. Around 30 months after the surgery, she developed carcinomatous pericardial tamponade, carcinomatous pleurisy, and metastatic thyroid cancer due to the breast cancer. Around the same time, a BRCA2 mutation was confirmed. Thus, olaparib therapy was started. Around 45 days after the start of olaparib administration, the therapeutic effect was cPR. The treatment remains effective even after approximately 1 year.
要旨
症例は70歳,女性。左乳癌,cT2N2M0,triple negativeの診断で術前化学療法を施行していた。術後約30か月目に癌性心膜炎による心タンポナーデの発症を機に,癌性胸膜炎,甲状腺転移も明らかとなり,同時にBRCA2遺伝子変異陽性が認められたためオラパリブを開始した。開始から1.5か月の評価CTでPR(RECIST v1.1)を確認した。現在,使用から約1年が経過するが副作用は軽微でQOLを維持し著効している。
目次
A 70-year-old woman was diagnosed with cT2N2M0 left triple negative breast cancer. She received neoadjuvant chemotherapy. Around 30 months after the surgery, she developed carcinomatous pericardial tamponade, carcinomatous pleurisy, and metastatic thyroid cancer due to the breast cancer. Around the same time, a BRCA2 mutation was confirmed. Thus, olaparib therapy was started. Around 45 days after the start of olaparib administration, the therapeutic effect was cPR. The treatment remains effective even after approximately 1 year.
要旨
症例は70歳,女性。左乳癌,cT2N2M0,triple negativeの診断で術前化学療法を施行していた。術後約30か月目に癌性心膜炎による心タンポナーデの発症を機に,癌性胸膜炎,甲状腺転移も明らかとなり,同時にBRCA2遺伝子変異陽性が認められたためオラパリブを開始した。開始から1.5か月の評価CTでPR(RECIST v1.1)を確認した。現在,使用から約1年が経過するが副作用は軽微でQOLを維持し著効している。